Chinese Guideline for Diagnosis and Management of Drug ⁃ induced Liver Injury (2023 Version)
10.3760/cma.j.cn501113.20230419.00176
- Author:
Yimin MAO
1
Author Information
1. Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Research Center of Fatty Liver Disease
- Publication Type:Journal Article
- Keywords:
Diagnosis;
Drug⁃Induced Liver Injury;
Guidelines;
Management;
Therapy
- From:
Chinese Journal of Gastroenterology
2022;27(6):341-375
- CountryChina
- Language:Chinese
-
Abstract:
Drug⁃induced liver injury (DILI) is an important adverse drug reaction that can lead to acute liver failure or even death in severe cases. Currently, the diagnosis of DILI still follows the strategy of exclusion. Therefore, a detailed history taking and a thorough and careful exclusion of other potential causes of liver injury is the key to correct diagnosis. This guideline was developed based on evidence⁃based medicine provided by the latest research advances and aims to provide professional guidance to clinicians on how to identify suspected DILI timely and standardize the diagnosis and management in clinical practice. Based on the clinical settings in China, the guideline also specifically focused on DILI in chronic liver diseases, drug ⁃ induced viral hepatitis reactivation, common causing agents of DILI (herbal and dietary supplements, anti⁃tuberculosis drugs, antineoplastic drugs), and signal and assessment of DILI in clinical trials.
